Related Experiment Video
Updated: Jul 12, 2025
A Protocol for Measuring Cue Reactivity in a Rat Model of Cocaine Use Disorder
Published on: June 18, 2018
Abstract:
Preliminary results from phase I trials respectively evaluating RMC-6236, a pan-RAS inhibitor, and HRS-4642, a KRASG12D inhibitor, indicate that both are safe and show promising signs of antitumor activity. These are just two of the candidate RAS therapies in a burgeoning development space as the field looks ahead to drugs that hit more than just KRASG12C.
Insights
Preliminary trials show RMC-6236, a pan-RAS inhibitor, and HRS-4642, a KRASG12D inhibitor, are safe and effective. These novel RAS therapies demonstrate promising antitumor activity, expanding treatment options beyond KRASG12C.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- RAS proteins are key drivers in many cancers.
- Targeting RAS mutations, particularly KRAS, is a significant therapeutic challenge.
- Existing therapies often focus on specific KRAS mutations like KRASG12C.
Purpose of the Study:
- To evaluate the safety and preliminary antitumor activity of novel RAS inhibitors.
- To explore the potential of pan-RAS inhibitors and specific KRAS inhibitors in cancer treatment.
- To assess the therapeutic landscape beyond KRASG12C-specific drugs.
Main Methods:
- Phase I clinical trials were conducted.
- RMC-6236 (pan-RAS inhibitor) and HRS-4642 (KRASG12D inhibitor) were evaluated.
- Safety and signs of antitumor activity were assessed.
Main Results:
- Both RMC-6236 and HRS-4642 demonstrated a favorable safety profile in Phase I trials.
- Preliminary data indicate promising signs of antitumor activity for both agents.
- These results support further development of these novel RAS-targeted therapies.
Conclusions:
- RMC-6236 and HRS-4642 represent promising new therapeutic candidates for RAS-driven cancers.
- The development of broader RAS inhibitors and inhibitors for other KRAS mutations is advancing.
- These findings contribute to the expanding field of RAS-targeted cancer therapy.
